Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125553223 | 12555322 | 3 | F | 20100301 | 20160812 | 20160714 | 20160825 | EXP | BR-AMGEN-BRASP2010005247 | AMGEN | 46.00 | YR | A | F | Y | 57.00000 | KG | 20160824 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125553223 | 12555322 | 1 | PS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, WEEKLY | E26608 | 103795 | 50 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 125553223 | 12555322 | 2 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, WEEKLY | 103795 | 50 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||||
| 125553223 | 12555322 | 3 | SS | INFLIXIMAB | INFLIXIMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 125553223 | 12555322 | 4 | C | REMICADE | INFLIXIMAB | 1 | UNK | 0 | |||||||||||
| 125553223 | 12555322 | 5 | C | METHOTREXATE. | METHOTREXATE | 1 | 15 MG, WEEKLY (2.5MG TABLETS, 3 IN THE MORNING AND 3 AT NIGHT) | 0 | 15 | MG | /wk | ||||||||
| 125553223 | 12555322 | 6 | C | METHOTREXATE. | METHOTREXATE | 1 | 0 | ||||||||||||
| 125553223 | 12555322 | 7 | C | ENDOFOLIN | FOLIC ACID | 1 | 5 MG ONCE DAILY ON 2 CONSECUTIVE DAYS TO USE OF ENBREL | 0 | |||||||||||
| 125553223 | 12555322 | 8 | C | ENDOFOLIN | FOLIC ACID | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125553223 | 12555322 | 1 | Psoriasis |
| 125553223 | 12555322 | 2 | Psoriatic arthropathy |
| 125553223 | 12555322 | 3 | Product used for unknown indication |
| 125553223 | 12555322 | 5 | Psoriasis |
| 125553223 | 12555322 | 6 | Psoriatic arthropathy |
| 125553223 | 12555322 | 7 | Adverse drug reaction |
| 125553223 | 12555322 | 8 | Adverse event |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125553223 | 12555322 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125553223 | 12555322 | Blood uric acid increased | |
| 125553223 | 12555322 | Drug ineffective | |
| 125553223 | 12555322 | Guttate psoriasis | |
| 125553223 | 12555322 | Hypersensitivity | |
| 125553223 | 12555322 | Incorrect dose administered | |
| 125553223 | 12555322 | Intentional product misuse | |
| 125553223 | 12555322 | Product quality issue | |
| 125553223 | 12555322 | Psoriasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125553223 | 12555322 | 1 | 20100301 | 0 | ||
| 125553223 | 12555322 | 2 | 2010 | 0 | ||
| 125553223 | 12555322 | 4 | 2008 | 0 | ||
| 125553223 | 12555322 | 5 | 201010 | 0 | ||
| 125553223 | 12555322 | 7 | 201010 | 0 |